Daily Stock Analysis, FLKS, Flex Pharma Inc, priceseries

Flex Pharma Inc. Daily Stock Analysis
Stock Information
Open
3.61
Close
3.78
High
3.78
Low
3.61
Previous Close
3.68
Daily Price Gain
0.10
YTD High
3.88
YTD High Date
Jan 7, 2020
YTD Low
3.60
YTD Low Date
Jan 9, 2020
YTD Price Change
0.13
YTD Gain
3.56%
52 Week High
24.45
52 Week High Date
Jul 11, 2019
52 Week Low
2.91
52 Week Low Date
Nov 20, 2019
52 Week Price Change
-4.60
52 Week Gain
-54.87%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 6. 2017
122.75
Mar 7. 2017
135.50
1 Trading Days
10.39%
Link
LONG
Jun 16. 2017
89.50
Jun 28. 2017
97.72
8 Trading Days
9.18%
Link
LONG
Sep 20. 2017
89.00
Sep 22. 2017
93.88
2 Trading Days
5.48%
Link
LONG
Nov 1. 2017
76.00
Dec 5. 2017
101.50
23 Trading Days
33.56%
Link
LONG
Mar 7. 2018
116.75
Mar 28. 2018
159.54
15 Trading Days
36.65%
Link
LONG
Oct 12. 2018
13.25
Oct 18. 2018
15.76
4 Trading Days
18.91%
Link
LONG
Oct 30. 2018
14.12
Oct 31. 2018
15.19
1 Trading Days
7.52%
Link
LONG
Mar 15. 2019
8.75
Mar 25. 2019
9.81
6 Trading Days
12.10%
Link
LONG
Apr 11. 2019
11.28
Apr 17. 2019
12.15
4 Trading Days
7.68%
Link
LONG
Jun 5. 2019
11.38
Jun 17. 2019
12.36
8 Trading Days
8.67%
Link
LONG
Jun 26. 2019
13.22
Jul 1. 2019
14.11
3 Trading Days
6.75%
Link
LONG
Jul 2. 2019
13.12
Jul 16. 2019
15.35
9 Trading Days
16.95%
Link
LONG
Aug 19. 2019
7.02
Aug 29. 2019
8.42
8 Trading Days
20.01%
Link
Company Information
Stock Symbol
FLKS
Exchange
NasdaqGM
Company URL
http://www.flex-pharma.com
Company Phone
617-874-1821
CEO
Christoph H. Westphal
Headquarters
Massachusetts
Business Address
800 BOYLSTON STREET, 24TH FLOOR, BOSTON, MA 02199
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001615219
About

Flex Pharma, Inc. operates as a biotechnology company, which engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions. The company was founded by Christoph Westphal and Jennifer M. Cermak on February 26, 2014 and is headquartered in Boston, MA.

Description

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development. Its lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis. The company also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. It markets and sells its HOTSHOT product online through its e-commerce Website, as well as through third-party Websites. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.